The Cancer Center at Illinois at the University of Illinois at Urbana-Champaign is supporting three new cancer research projects through its planning grant initiative. Recipients will each receive up to $25,000 to spark innovative research projects that have promise...
The Cancer Center at Illinois Appoints Veterinary Oncologist to Lead Research Program
Timothy M. Fan, Professor of Veterinary Oncology, has been appointed as program leader of the Cancer Center at Illinois (CCIL) research program in Cancer Discovery Platforms Across the Engineering-Biology Continuum. Fan will co-lead this research program with Brendan...
Cancer Center at Illinois Appoints New Deputy Director
Paul J. Hergenrother, the Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry and Professor of Chemistry, has been appointed the Cancer Center at Illinois (CCIL) Deputy Director effective March 1, 2020. Paul currently co-leads the CCIL research...
CCIL Program Leader Elected AAAS Fellow
Paul HergenrotherPaul Hergenrother, professor of chemistry and leader of the CCIL Program 2 (Cancer Discovery Platforms Bridging the Engineering-Biology Continuum), is one of eight Illinois faculty members elected as a 2019 Fellow of the American Association for the...
CCIL Member Creates New Web App That Identifies Drug Compounds
The team includes, from left, graduate student Emily Geddes, pathobiology professor Gee Lau, chemistry professor Paul Hergenrother, postdoctoral researcher Hyang Yeon Lee, and postdoctoral researcher Erica Parker.Paul Hergenrother, professor of chemistry, collaborated...
Teaming Up to “Krush Cancer”: CCIL and Illini Basketball Highlights
CRAG Members at Illini Basketball GameThe Cancer Center at Illinois and the Division of Intercollegiate Athletics teamed up on Wednesday night to help draw awareness to cancer, and while the men’s Basketball Team ultimately lost to the Wisconsin Badgers, the Cancer...
PAC-1 Trial in Humans with Brain Cancer Extended
Timothy Fan and Paul HergenrotherA drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the...